Validation of a protein panel for the noninvasive detection of recurrent non-muscle invasive bladder cancer

Abstract

Context: About 50–70% of patients with non-muscle invasive bladder cancer (NMIBC) experience relapse of disease.

Objective: To establish a panel of protein biomarkers incorporated in a multiplexed microarray (BCa chip) and a classifier for diagnosing recurrent NMIBC.

Materials and methods: Urine samples from 45 patients were tested. Diagnostic performance was evaluated by receiver operating characteristic (ROC) analysis.

Results: A multi biomarker panel (ECadh, IL8, MMP9, EN2, VEGF, past recurrences, BCG therapies and stage at diagnosis) was identified yielding an area under the curve of 0.96.

Discussion and conclusion: This biomarker panel represents a potential diagnostic tool for noninvasive diagnosis of recurrent NMIBC.

Keywords:

• Recurrent bladder cancer
• ECadh
• IL8
• MMP9
• EN2
• VEGF

Acknowledgements

The authors thank the European Commission for financial support within FP7 Dipromon (Development of an integrated protein- and cell-based device for noninvasive diagnostics in the urogenital tract, no. 306157).

Disclosure statement

The authors report no declarations of interest.

Additional information

Funding

European Commission [306157] and Seventh Framework Programme [Dipromon / no. 306157].